SEARCH

SEARCH BY CITATION

References

  • 1
    Tolkoff-Rubin NE, Rubin RH. The impact of cytomegalovirus infection on graft function and patient outcome. Graft 1999; 2: S1013.
  • 2
    Vanèiková Z, Dvorãk P. Cytomegalovirus infection in immunocompetent and immunocompromised individuals – a review. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 179187.
  • 3
    Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999; 1: 812.
  • 4
    Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 36073609.
  • 5
    Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742751.
  • 6
    Reusser P. Oral valganciclovir. a new option for the treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs 2001; 10: 17451753.
  • 7
    Lowance D, Neumayer H-H, Legendre CM et al.. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 14621470.
  • 8
    Razonable RR, Rivero A, Rodriguez A et al.. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 14611464.
  • 9
    Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev 2000: CD001320.
  • 10
    Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995; 60: 13571360.
  • 11
    Noble S, Faulds D, Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998; 56: 115146.
  • 12
    Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997; 64: 16141617.
  • 13
    Gane E, Saliba F, Valdecasas GJC et al.. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 17291733.
  • 14
    Flechner SM, Avery RK, Fisher R et al.. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66: 16821688.
  • 15
    Paya CV, Wilson JA, Espy MJ et al.. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854860.
  • 16
    Pescovitz MD, Rabkin J, Merion RM et al.. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 28112815.
  • 17
    Pescovitz MD, Pruett TL, Gonwa T et al.. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998; 66: 11041107.
  • 18
    Singh N, Yu, VL. Guyowski T, Marino IR. Changes in the level of CMV antigenemia (pp65) in liver transplant recipients receiving oral ganciclovir as CMV prophylaxis. Transplantation 1999; 67: S98.
  • 19
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645649.
  • 20
    Martin DF, Sierra-Madero J, Walmsley S et al.. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 11191126.
  • 21
    Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impariment. Clin Pharmacol Ther 2002; 72: 142150.
  • 22
    Razonable RR, Brown RA, Espy MJ, Rivero A, Kremers W, Wilson J. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001; 39: 44724476.
  • 23
    Razonable RR, Brown RA, Wilson J et al.. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002; 73: 968973.
  • 24
    Demonstrating equivalence. In: Elashoff, JD, ed. nQuery Advisor Release 5 User Guide. Los Angeles : Statistical Solutions, 2002; 11-111-26.
  • 25
    Gane E, Saliba F, Valdecasas GJ et al.. Randomised trial of efficacy and safety of oral ganciclovir in prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 17291733.
  • 26
    Organ Procurement and Transplantation Network. All Kaplan-Meier patient survival rates for transplants performed, 1996–2001, and all Kaplan-Meier graft survival rates for transplants performed 24 October 2003, 1996–2001. URL http://www.optn.org.
  • 27
    Boivin G, Goyette N, Gilbert C et al.. Low frequency of emergence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in solid organ transplant patients receiving valganciclovir or oral ganciclovir prophylaxis. Am J Transplant 2003; 3 (Suppl. 5): S431.
  • 28
    Boeckh M, Leisenring W, Riddell SR et al.. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407414.
  • 29
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV) -specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979.
  • 30
    Sester M, Sester U, Gartner BC, Girndt M, Meyerhans A, Kohler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 25772584.
  • 31
    Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592599.
  • 32
    Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001; 23: 12961300.